Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 15/20 | 0.56 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29890782 | 0.92 | FURIN (0.53) | FURINCACNA1IKCNH2FAAHBCHE | |
| SCHEMBL21564564 | 0.92 | FURIN (0.53) | FURINCACNA1IKCNH2FAAHBCHE | |
| SCHEMBL21550895 | 0.91 | FURIN (0.56) | FURINCACNA1IKCNH2FAAHBCHE | |
| SCHEMBL29928557 | 0.91 | FURIN (0.56) | FURINCACNA1IKCNH2FAAHBCHE | |
| SCHEMBL29198900 | 0.89 | FURIN (0.53) | FURINCACNA1IKCNH2FAAHBCHE | |
| SCHEMBL21551389 | 0.83 | FURIN (0.59) | FURINCACNA1IKCNH2FAAHBCHE | |
| SCHEMBL21553796 | 0.80 | FURIN (0.44) | FURIN | |
| SCHEMBL26077400 | 0.80 | FURIN (0.63) | FURINCACNA1IKCNH2 | |
| SCHEMBL21551558 | 0.79 | FURIN (0.65) | FURINCACNA1IKCNH2 | |
| SCHEMBL21551709 | 0.79 | FURIN (0.81) | FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3790871-B1 | FURIN INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-3790871-A1 | FURIN INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215341-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315556-A1 | FURIN INHIBITORS | FURIN, TGFB1, PCSK7 | FURIN 1/4885CACNA1I 4442/4885KCNH2 3663/4885 |
| US-11773078-B2 | Furin inhibitors | FURIN, TGFB1, PCSK7 | FURIN 1/4885CACNA1I 4442/4885KCNH2 3663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.